About: Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases
Creator	Kumar, Rajesh Awasthi, Rajendra Collet, Trudi Deeksha, Dua, Kamal Gupta, Gaurav Mehta, Meenu Negi, Poonam Pandey, Parijat Satija, Saurabh Singh, Harjeet Tewari, Devesh Thangavelu, Lakshmi Wadhwa, Ridhima Hansbro, Philip Chellappan, Kumar
source	Elsevier; Medline; PMC
abstract	Abstract Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.
has issue date	2019-08-01(xsd:dateTime)
bibo:doi	10.1016/j.cbi.2019.05.028
bibo:pmid	31136735
has license	els-covid
sha1sum (hex)	79943ae7607d2c825bc91a397a6b4ecfd7ceca04
schema:url	https://doi.org/10.1016/j.cbi.2019.05.028
resource representing a document's title	Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases
has PubMed Central identifier	PMC7094617
has PubMed identifier	31136735
schema:publication	Chemico-Biological Interactions
resource representing a document's body	covid:79943ae7607d2c825bc91a397a6b4ecfd7ceca04#body_text
is schema:about of	named entity 'THERAPY' named entity 'INTERACTIONS' named entity 'RESPIRATORY DISEASES' named entity 'BIOLOGICAL' named entity 'OLIGONUCLEOTIDE' named entity 'CHRONIC' named entity 'INFLAMMATORY' named entity 'DRUG DELIVERY' named entity 'chronic' named entity 'drug delivery' named entity 'Biological Interactions' named entity 'oligonucleotides' named entity 'RSV' named entity 'allergens' named entity 'monoclonal antibodies' named entity 'RNA-induced silencing complex' named entity 'chitosan' named entity 'ASOs' named entity 'chitosan' named entity 'inhalation' named entity 'non-coding RNAs' named entity 'oligonucleotide' named entity 'respiratory infections' named entity 'non-specific' named entity 'carcinoma' named entity 'allergen' named entity 'COPD' named entity 'epithelium' named entity 'alpha-actin' named entity 'delivery of drugs' named entity 'asthma' named entity 'antisense oligonucleotide' named entity 'siRNA' named entity 'alveolar epithelial cells' named entity 'chronic disease' named entity 'airway hyper-responsiveness' named entity 'collagen' named entity 'Mycobacterium tuberculosis' named entity 'target specific' named entity 'siRNA' named entity 'nanoparticles' named entity 'guanine' named entity 'siRNA' named entity 'methylated' named entity 'macrophages' named entity 'BCL2' named entity 'antisense oligonucleotide' named entity 'aerosols' named entity 'liposomes' named entity 'pDC' named entity 'DNCs' named entity 'inhalation' named entity 'lipid' named entity 'micelles' named entity 'T-cell' named entity 'Nanoparticle' named entity 'EGFR' named entity 'micelle' named entity 'target gene' named entity 'liposomes' named entity 'intranasal' named entity 'inhaled corticosteroids' named entity 'nucleotides' named entity 'influenza A virus' named entity 'small molecule' named entity 'oligonucleotide'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software